Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

• The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint of reduced COVID-19 mortality, compared with SoC¹
  
  
• Ilaris^® (canakinumab) remains an effective treatment option for its approved indications, with a well-characterized safety profile ^2,3. The safety profile of canakinumab plus SoC in CAN-COVID was comparable to placebo plus SoC¹
  
  
• Interim Day 29 results will be submitted for peer-reviewed publication to further support the scientific understanding of COVID-19 infection and potential treatments
  
  
• Novartis further strengthened its pandemic response efforts by collaborating with Molecular Partners to develop two DARPin^® therapies for potential use against COVID-19⁴. In addition, a Phase III trial for ruxolitinib in COVID-19 is ongoing, with preliminary results expected by year end⁵

Basel, November 6, 2020 — Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)⁶. The ongoing trial failed to meet its primary endpoint showing that treatment with canakinumab plus standard of care (SoC) did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus SoC up to Day 29¹. The trial did not meet its key secondary endpoint of reducing the COVID-19-related death rate during the 4-week period after treatment¹. The safety profiles of canakinumab plus SoC and placebo plus SoC were comparable¹.

“Though the CAN-COVID trial did not show the patient benefit we were hoping for, it helps improve the scientific understanding of COVID-19 and the role of interleukin-1β inhibition,” said John Tsai, M.D., Head of Global Drug Development and Chief Medical Officer for Novartis. “There’s still an urgent need for effective ways to combat COVID-19 and we will continue to apply our best scientific minds in support of the global pandemic response, including a Phase III trial of ruxolitinib. We’re deeply grateful to the patients who participated and their caregivers, as well as the healthcare professionals and hospital staff who made this research possible while fighting the pandemic on the front line.”

In the trial, the primary endpoint of survival without the need for mechanical ventilation was 88.8% for canakinumab plus SoC vs 85.7% for placebo plus SoC (P=0.29)¹. The key secondary endpoint of COVID-19-related mortality up to 4 weeks was 4.9% for canakinumab plus SoC vs 7.2% for placebo plus SoC (P=0.33)¹. Both the primary and key secondary endpoints trended in favor of canakinumab but did not reach statistical significance¹. No new safety signals for canakinumab were identified¹.

This interim analysis will be submitted to a peer-reviewed journal in the coming weeks. The CAN-COVID results do not affect any other ongoing trials for canakinumab, including investigations for the treatment of non-small cell lung cancer (NSCLC)^7-9.

As part of its continued efforts to support the global pandemic response, Novartis in October announced a collaboration with Switzerland-based Molecular Partners to develop two DARPin^® therapies designed for potential use against COVID-19⁴. In addition, a Phase III trial for ruxolitinib in COVID-19 is ongoing, with preliminary results expected by year end⁵.

About CAN-COVID
CAN-COVID is a Phase III, multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of canakinumab plus standard of care (SoC) in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)⁶. Patients were hypoxic but not requiring intubation or invasive mechanical ventilation⁶. The primary endpoint was to demonstrate the benefit of canakinumab plus SoC vs placebo plus SoC in increasing the chance of survival without the need for invasive mechanical ventilation up to Day 29⁶. The key secondary endpoint was to reduce the COVID-19-related death rate during the 4-week period after trial treatment⁶. The trial enrolled 454 patients at multiple centers across the US, Russia and Europe¹. Both endpoints were analyzed at Day 29⁶. The average age of trial participants was 58 years old, ranging from 18 to 98 years old¹. Approximately 30% were Hispanic or Latino, 16% were Black or African American and 4% were Asian¹. Interim analysis of Day 29 results is available. The trial is ongoing (to Day 127) with full results expected in early 2021⁶.

About canakinumab
Canakinumab is biologic medicine used in the treatment of a number of rare, debilitating auto-inflammatory diseases, for which there are limited options available. It is a monoclonal antibody that binds to and neutralizes interleukin-1 beta (IL-1β), blocking its action^2,3,10. Excessive production of IL-1β plays a prominent role in certain inflammatory diseases and immune responses^11,12. Canakinumab is an established medicine approved under the trade name Ilaris^® in approximately 60 countries including the US, Europe and others. It is indicated for rare conditions including periodic fever syndromes, adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA)^2,3. First approved in 2009, canakinumab has been proven to be highly effective and well tolerated as a treatment option for its approved indications based on previously reported clinical trials^2,3. As well as being studied in severe COVID-19, canakinumab is also being investigated for the treatment of a number of other diseases involving inflammation, including non-small cell lung cancer (NSCLC)^7-9.

Novartis response to COVID-19 pandemic
Novartis is making multiple contributions to the global effort to combat the COVID-19 pandemic and support the stability of global healthcare systems. The company has committed to donating USD 40 million to support communities around the world impacted by the pandemic. In addition, Novartis is active in several key cross-industry research initiatives, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard as well as a COVID-19 directed partnership supported by the Innovative Medicines Initiative (IMI)¹³. Novartis has also announced a collaboration with Molecular Partners to develop two DARPin^® therapies designed for potential use against COVID-19, and the company is separately supporting COVID-19-related clinical investigations of several Novartis medicines⁴. We continue with the Phase III trial for ruxolitinib, another Novartis medicine, in collaboration with Incyte⁵. Preliminary results from this trial are expected by year end. Two medicines in early stage development are also being investigated focusing on stopping or slowing the body’s overactive immune response to COVID-19^{14, 15}. In our labs, we have started a collaborative, longer-term drug discovery effort to develop an antiviral molecule to potentially treat all coronaviruses. To sustain access, the Novartis generics and biosimilars division Sandoz became the first company to commit to keeping stable prices for a basket of essential medicines that may help in the treatment of COVID-19 and entered into a partnership with US-based Civica Rx to support stable supply of essential generic hospital medicines. We are making 15 drugs that treat key symptoms of COVID-19 available to low- and lower-middle income countries at zero profit until a vaccine or curative treatment is found. This includes dexamethasone, which is the only medicine shown to decrease mortality so far in severe hospitalized COVID pneumonia¹³. Furthermore, Novartis Gene Therapies entered into a manufacturing agreement with Massachusetts Eye and Ear and Massachusetts General Hospital to produce its novel genetic COVID-19 vaccine candidate called AAVCOVID¹⁶. More information about the Novartis response to COVID-19 is available at www.Novartis.com/coronavirus

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]

References

# # #

Novartis Media Relations
E-mail: [email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]